Nimbus Discovery

Headlines

May 8, 2013
Nimbus and Shire to Co-Develop Therapies for Rare Diseases: February 6, 2013
Wes Westlin Appointed Head of Preclinical Research and Early Development

Selected Publications & Posters

POSTER: ACC Inhibition by ND-630: 2013 Keystone Meeting
POSTER: IRAK4 Inhibitors in Arthritis: 2012 ACR Annual Meeting

Welcome to Nimbus Discovery

Nimbus Discovery harnesses cutting-edge computational technologies to uncover breakthroughs in small molecule pharmacology. Nimbus focuses on medically important and highly sought-after disease targets that have proven inaccessible to traditional industry approaches. Nimbus’ robust pre-clinical pipeline includes novel agents for the treatment of cancer, metabolic disease and inflammation. Founded in 2009, Nimbus partnered with Schrödinger to invent and apply a physics-based approach that establishes a new standard for rational drug design.